Jove
Visualize
Contact Us

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Drug Toxicity: Overview01:00

Drug Toxicity: Overview

Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current and emerging therapies targeting cell surface antigens and epigenetics in extensive stage small cell lung cancer: primer for clinicians.

Therapeutic advances in medical oncology·2026
Same author

A case report of acute carcinoid heart failure during lutetium-177 dotatate-triapine treatment for well-differentiated neuroendocrine tumors.

Frontiers in oncology·2026
Same author

Inhibition of ribonucleotide reductase subunit M2 enhances the radiosensitivity of metastatic pancreatic neuroendocrine tumor.

Cancer letters·2024
Same author

Prescribing Characteristics of Octreotide Immediate-Release and Long-Acting Release in Patients with Neuroendocrine Tumors.

The oncologist·2023
Same author

hPG<sub>80</sub> (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors.

Cancers·2022
Same author

<sup>68</sup>Ga-DOTATATE PET/CT: The Optimum Standardized Uptake Value (SUV) Internal Reference.

Academic radiology·2021
Same journal

Practical prescribing in cancer cachexia.

Current opinion in supportive and palliative care·2026
Same journal

Recent advances in autoantibody-mediated pain.

Current opinion in supportive and palliative care·2026
Same journal

Functional and molecular diversity of human C-fibers in pain modulation.

Current opinion in supportive and palliative care·2026
Same journal

The multidimensional impact of malnutrition in incurable cancer.

Current opinion in supportive and palliative care·2026
Same journal

The forgotten burden: nutrition impact symptoms in colorectal cancer survivorship.

Current opinion in supportive and palliative care·2026
Same journal

Cortical and brainstem mechanisms of pain: linking defensive responses, descending modulation, and affective-sensory integration.

Current opinion in supportive and palliative care·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 3, 2026

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

Irinotecan toxicity.

Lowell Anthony1

  • 1Louisiana State University Health Sciences Center, Stanley S Scott Cancer Center, New Orleans, Louisiana 70012, USA. lantho@lsuhsc.edu

Current Opinion in Supportive and Palliative Care
|July 29, 2008
PubMed
Summary
This summary is machine-generated.

Irinotecan toxicity is manageable, but genetic factors like UGT1A polymorphisms and liver function impact patient risk. Dose adjustments and octreotide LAR can effectively manage side effects like diarrhea and neutropenia.

Related Experiment Videos

Last Updated: Jul 3, 2026

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

Area of Science:

  • Oncology
  • Pharmacogenomics
  • Gastroenterology

Background:

  • Irinotecan is a vital chemotherapy agent, but its toxicity presents a clinical challenge.
  • Managing irinotecan-induced adverse events requires understanding interindividual variability.
  • Recent research explores genetic factors and clinical conditions influencing irinotecan toxicity.

Purpose of the Study:

  • To review current understanding of irinotecan toxicity.
  • To highlight recent findings on managing irinotecan-induced side effects.
  • To discuss factors influencing irinotecan toxicity and management strategies.

Main Methods:

  • Literature review of recent studies on irinotecan toxicity.
  • Analysis of pharmacogenomic data, specifically UGT1A polymorphisms.
  • Evaluation of clinical data on hepatic dysfunction and chemotherapy-induced diarrhea.

Main Results:

  • UGT1A polymorphisms are associated with increased risk of irinotecan-induced diarrhea and neutropenia.
  • Dose adjustment of irinotecan is recommended for patients with hepatic dysfunction.
  • 'Chemo' liver is a recognized complication in neoadjuvant settings.
  • Octreotide LAR at 30 mg is effective in managing chemotherapy-induced diarrhea.

Conclusions:

  • Hepatic insufficiency and UGT1A polymorphisms increase irinotecan toxicity risk.
  • Established protocols for dose adjustment in hepatic insufficiency are crucial.
  • Management of 'chemo' liver impacts advanced colorectal cancer treatment.
  • Octreotide LAR (30 mg) provides adequate control for most patients experiencing chemotherapy-induced diarrhea.